Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Rogers Sciences Inc.
With
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Tufts Medical Center
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients \> 18 years of age, with primary or metastatic cutaneous tumors that may or may not have been previously irradiated.
ECOG performance status \< 3.
Patients must not have received any systemic anti-cancer therapy within 30 days prior to enrolling in this study.
Patients must not have received radiation therapy to the target site within 60 days of enrolling on this study.
Skin of target site and control site must be grade 0 or 1 by Common Terminology
Patients must have a target lesion and normal peri-umbilical skin that can be covered by the fiber-optic mesh used to deliver CLIPT (10 x 10 cm, or 3 x 3).
If located on an extremity, the target lesion must not cover more than 50% of the diameter of the extremity at the level at which it is located.
Absolute neutrophil count \> 1000.
Adequate coagulation status as indicated by platelet count \> 50,000, PT and PTT \< 1.5 time the upper limit of normal.
Patients must sign informed consent.
You may not be if
Male patients not considered for this study.
Patients must have a target lesion in a location other than the hands, feet, genitals, or face. Lesions in those locations will be excluded.
Patients with medical conditions associated with photosensitivity, such as cutaneous porphyria or a collagen vascular disease, or with known allergies to porphyrins will be excluded.
Pregnant and nursing patients will be excluded. Women of child-bearing potential must have a negative serum or urine pregnancy test prior to enrollment.
Patients taking medications known to cause photosensitivity (tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics, griseofulvin, and fluoroquinolones, St. John's wort and amiodarone) will be excluded.
Patients with severe hepatic dysfunction (total bilirubin, AST, or ALT \> five times upper limit of normal) will be excluded.
Clareo Health | A Novel Therapy for the Treatment of Chest Wall Progression of Breast Cancer
